Campbell & CO Investment Adviser LLC Grows Stock Holdings in Encompass Health Corporation $EHC

Campbell & CO Investment Adviser LLC raised its stake in Encompass Health Corporation (NYSE:EHC) by 16.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 23,437 shares of the company’s stock after buying an additional 3,246 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in Encompass Health were worth $2,874,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of EHC. WPG Advisers LLC purchased a new position in Encompass Health in the 1st quarter valued at approximately $27,000. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Encompass Health by 749.0% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 416 shares of the company’s stock valued at $42,000 after buying an additional 367 shares in the last quarter. Parkside Financial Bank & Trust raised its stake in shares of Encompass Health by 179.5% during the 2nd quarter. Parkside Financial Bank & Trust now owns 478 shares of the company’s stock worth $59,000 after buying an additional 307 shares during the last quarter. Park Place Capital Corp purchased a new stake in shares of Encompass Health in the 2nd quarter worth about $72,000. Finally, Caitong International Asset Management Co. Ltd grew its stake in Encompass Health by 19.0% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 720 shares of the company’s stock valued at $73,000 after acquiring an additional 115 shares during the last quarter. Hedge funds and other institutional investors own 97.25% of the company’s stock.

Encompass Health Stock Performance

NYSE EHC opened at $115.18 on Monday. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.06 and a quick ratio of 1.06. Encompass Health Corporation has a 1-year low of $87.85 and a 1-year high of $127.99. The firm has a market capitalization of $11.59 billion, a P/E ratio of 21.77, a P/E/G ratio of 2.20 and a beta of 0.91. The business’s 50-day simple moving average is $123.54 and its 200-day simple moving average is $119.64.

Encompass Health (NYSE:EHC) last posted its quarterly earnings results on Wednesday, March 16th. The company reported $0.93 EPS for the quarter. Encompass Health had a net margin of 9.33% and a return on equity of 18.19%. The firm had revenue of $136.30 million for the quarter. Encompass Health has set its FY22 guidance at $3.83-$4.19 EPS. Equities analysts predict that Encompass Health Corporation will post 4.8 EPS for the current year.

Encompass Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Friday, January 2nd will be given a dividend of $0.19 per share. This represents a $0.76 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Friday, January 2nd. Encompass Health’s dividend payout ratio is 14.37%.

Insider Transactions at Encompass Health

In other Encompass Health news, EVP Patrick William Tuer sold 1,020 shares of the firm’s stock in a transaction dated Wednesday, August 27th. The stock was sold at an average price of $123.59, for a total value of $126,061.80. Following the transaction, the executive vice president directly owned 18,846 shares of the company’s stock, valued at $2,329,177.14. This trade represents a 5.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 2.00% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on EHC shares. KeyCorp lifted their target price on shares of Encompass Health from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. Zacks Research raised Encompass Health from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 21st. UBS Group increased their target price on Encompass Health from $140.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, October 2nd. Weiss Ratings reissued a “buy (b+)” rating on shares of Encompass Health in a report on Wednesday, October 8th. Finally, Raymond James Financial raised Encompass Health to a “strong-buy” rating in a research note on Friday, October 31st. Three investment analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company’s stock. According to MarketBeat.com, Encompass Health currently has an average rating of “Buy” and a consensus price target of $142.86.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.